Evidence map›Paper›PMID 18512030›Full record

ReviewArchivum immunologiae et therapiae experimentalis

Manipulating B cell homeostasis: a key component in the advancement of targeted strategies.

Laura S Treml, William J Quinn, John F Treml, Jean L Scholz, Michael P Cancro

Abstract readReview
In one paragraph

Review in Archivum immunologiae et therapiae experimentalis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. B cells and transplantation tolerance.Nature reviews. Nephrology · 2010
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura S TremlDepartment of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6082, USA.
William J Quinn
John F Treml
Jean L Scholz
Michael P Cancro

Funding

Immune System Development and RegulationT32AI055428 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ALLMAN, DAVID M, OLIVER, PAULA MARIA · 2003 to 2025
$4.2M
Transitional B cell selection during peripheral B lymphopenia and reconstitutionR01AI073939 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CANCRO, MICHAEL PAUL · 2007 to 2011
$2.1M
ROLE OF BLYS IN PERIPHERAL B CELL SELECTION AND SURVIVALR01AI054488 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CANCRO, MICHAEL PAUL · 2004 to 2008
$1.9M
NIAID NIH HHS R01 AI054488NIAID NIH HHS R01 AI073939NIAID NIH HHS T32 AI055428
6 · The paper itself

Abstract

Understanding the homeostatic mechanisms governing lymphocyte pools achieves critical importance as lymphocyte-targeted therapies expand in use and scope. The primacy of B lymphocyte stimulator (BLyS) family ligands and receptors in governing B lymphocyte homeostasis has become increasingly clear in recent years, affording insight into novel opportunities and potential pitfalls for targeted B cell therapeutics. Interclonal competition for BLyS-BR3 interactions determines the size of naïve B cell pools and can regulate the stringency of selection applied as cells complete maturation. Thus one of the predicted consequences of ablative therapies targeting primary pools is relaxed negative selection. This suggests that BLyS levels and B cell reconstitution rates may serve useful prognostic roles and that BLyS itself might be targeted to circumvent relapse. Alternatively, manipulations that allow rare, minimally autoreactive specificities to survive and mature may lead to opportunities in cases where antibody-based vaccine development has heretofore been unsuccessful. BLyS family ligands and receptors also play a role in activated and memory B cell pools, suggesting they might likewise be targeted to promote or delete particular antigen-experienced subpopulations in a similar way.

Indexed as

HomeostasisAnimalsB-Cell Activating FactorB-Cell Activation Factor ReceptorB-Cell Maturation AntigenB-LymphocytesHumansPlasma CellsToll-Like ReceptorsTumor Necrosis Factor Ligand Superfamily Member 13B-Cell Activating FactorB-Cell Activation Factor ReceptorB-Cell Maturation AntigenToll-Like ReceptorsTumor Necrosis Factor Ligand Superfamily Member 13

Identifiers

PMID18512030
PMCPMC2692354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.